Esperion Therapeutics (ESPR) Commences Pivotal Phase 3 Study for the Bempedoic Acid / Ezetimibe Combination Pill
Tweet Send to a Friend
Esperion Therapeutics, Inc. (NASDAQ: ESPR) today announced initiation of the pivotal Phase 3 study (1002FDC-053) to assess the efficacy and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
